March’s FDA approvals feature new biosimilars, first-in-class therapies, expanded indications, and diagnostic innovations across allergy, cardiology, gastroenterology, infectious diseases, and more.
Bavarian Nordic’s freeze-dried Jynneos vaccine offers logistical advantages over the liquid-frozen version, supporting long-term U.S. stockpiling and public health preparedness.
Investigators have identified distinct Gardnerella species with varying antibiotic resistance patterns, potentially guiding more effective treatment for recurrent bacterial vaginosis.
New research reveals 25% tariffs on Canadian pharmaceuticals would impact critical medications, strain supply chains, and potentially increase costs—with 28 drugs having no alternative suppliers.
Conexiant
Daily News
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
FDA approves gepotidacin, a first-in-class oral antibiotic, for treating uncomplicated urinary tract infections in females aged 12 and older, based on phase III trial results.
Children breastfed for 6+ months showed 27% lower odds of developmental delays and neurodevelopmental conditions in comprehensive Israeli analysis of 570,000+ children, with sibling comparisons confirming protective effects.